1 option
Valuing Rare Pediatric Drugs: An Economics Perspective / Rena M. Conti, Jonathan Gruber, Daniel A. Ollendorf, Peter J. Neumann.
- Format:
- Book
- Author/Creator:
- Conti, Rena M.
- Series:
- Working Paper Series (National Bureau of Economic Research) no. w27978.
- NBER working paper series no. w27978
- Language:
- English
- Physical Description:
- 1 online resource: illustrations (black and white);
- Place of Publication:
- Cambridge, Mass. National Bureau of Economic Research 2020.
- Summary:
- There is a coming wave of novel genetic therapies aiming to treat rare pediatric disease. A large literature investigates the valuation of new treatments, but the valuation of treatments for rare pediatric illness raises a host of unique issues. In this paper, we review the challenges of applying both the standard economic model and standard approaches to estimating cost-effectiveness using the quality-adjusted life year (QALY) to this case. We argue that there are a large number of special issues that have only been partially addressed by past work and we conclude that more data and the development of new methods are vital as innovators, health technology assessment practitioners and policymakers confront the launch of these new drugs.
- Notes:
- Print version record
- October 2020.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.